<DOC>
	<DOCNO>NCT02248155</DOCNO>
	<brief_summary>The objective Post Marketing Surveillance ( PMS ) : - Evaluation treatment effect pramipexole Restless Legs Syndrome ( RLS ) severity measure International Restless Legs Syndrome Scale ( IRLS ) Clinical Global Impression Improvement scale ( CGI- I ) - Evaluation time reach maintenance dose pramipexole - Evaluation work productivity impairment associate RLS base Work Productivity Activity Impairment Questionnaire ( WPAI ) questionnaire</brief_summary>
	<brief_title>Observational Study SifrolÂ® Patients With Primary Restless Legs Syndrome ( RLS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Patients suffer primary RLS eligible Pramipexol ( PPX ) treatment could include study Patients pretreated dopaminergic agent ( de novo patient ) patient pretreated dopaminergic medication Male female patient age The treating physician ask consider regulation describe Summary Product Characteristics ( SmPC ) treatment pramipexole</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>